Matches in SemOpenAlex for { <https://semopenalex.org/work/W1570208766> ?p ?o ?g. }
- W1570208766 endingPage "65" @default.
- W1570208766 startingPage "54" @default.
- W1570208766 abstract "Object The object of this study was to define the long-term outcomes and risks of arteriovenous malformation (AVM) management using 2 or more stages of stereotactic radiosurgery (SRS) for symptomatic large-volume lesions unsuitable for surgery. Methods In 1992, the authors prospectively began to stage the treatment of anatomical components to deliver higher single doses to AVMs with a volume of more than 10 cm 3 . Forty-seven patients with such AVMs underwent volume-staged SRS. In this series, 18 patients (38%) had a prior hemorrhage and 21 patients (45%) underwent prior embolization. The median interval between the first-stage SRS and the second-stage SRS was 4.9 months (range 2.8–13.8 months). The median target volume was 11.5 cm 3 (range 4.0–26 cm 3 ) in the first-stage SRS and 9.5 cm 3 in the second-stage SRS. The median margin dose was 16 Gy (range 13–18 Gy) for both stages. Results In 17 patients, AVM obliteration was confirmed after 2–4 SRS procedures at a median follow-up of 87 months (range 0.4–209 months). Five patients had near-total obliteration (volume reduction > 75% but residual AVM). The actuarial rates of total obliteration after 2-stage SRS were 7%, 20%, 28%, and 36% at 3, 4, 5, and 10 years, respectively. The 5-year total obliteration rate after the initial staged volumetric SRS with a margin dose of 17 Gy or more was 62% (p = 0.001). Sixteen patients underwent additional SRS at a median interval of 61 months (range 33–113 months) after the initial 2-stage SRS. The overall rates of total obliteration after staged and repeat SRS were 18%, 45%, and 56% at 5, 7, and 10 years, respectively. Ten patients sustained hemorrhage after staged SRS, and 5 of these patients died. Three of 16 patients who underwent repeat SRS sustained hemorrhage after the procedure and died. Based on Kaplan-Meier analysis (excluding the second hemorrhage in the patient who had 2 hemorrhages), the cumulative rates of AVM hemorrhage after SRS were 4.3%, 8.6%, 13.5%, and 36.0% at 1, 2, 5, and 10 years, respectively. This corresponded to annual hemorrhage risks of 4.3%, 2.3%, and 5.6% for Years 0–1, 1–5, and 5–10 after SRS. Multiple hemorrhages before SRS correlated with a significantly higher risk of hemorrhage after SRS. Symptomatic adverse radiation effects were detected in 13% of patients, but no patient died as a result of an adverse radiation effect. Delayed cyst formation did not occur in any patient after SRS. Conclusions Prospective volume-staged SRS for large AVMs unsuitable for surgery has potential benefit but often requires more than 2 procedures to complete the obliteration process. To have a reasonable chance of benefit, the minimum margin dose should be 17 Gy or greater, depending on the AVM location. In the future, prospective volume-staged SRS followed by embolization (to reduce flow, obliterate fistulas, and occlude associated aneurysms) may improve obliteration results and further reduce the risk of hemorrhage after SRS." @default.
- W1570208766 created "2016-06-24" @default.
- W1570208766 creator A5011427447 @default.
- W1570208766 creator A5020032572 @default.
- W1570208766 creator A5022191739 @default.
- W1570208766 creator A5032556403 @default.
- W1570208766 creator A5042165288 @default.
- W1570208766 creator A5059099861 @default.
- W1570208766 creator A5061884581 @default.
- W1570208766 creator A5071859254 @default.
- W1570208766 creator A5077751691 @default.
- W1570208766 creator A5082744383 @default.
- W1570208766 date "2012-01-01" @default.
- W1570208766 modified "2023-10-16" @default.
- W1570208766 title "Stereotactic radiosurgery for arteriovenous malformations, Part 6: multistaged volumetric management of large arteriovenous malformations" @default.
- W1570208766 cites W1504212649 @default.
- W1570208766 cites W1508590061 @default.
- W1570208766 cites W1963567408 @default.
- W1570208766 cites W1970054953 @default.
- W1570208766 cites W1973470461 @default.
- W1570208766 cites W1973490080 @default.
- W1570208766 cites W1981053175 @default.
- W1570208766 cites W2005131595 @default.
- W1570208766 cites W2009217240 @default.
- W1570208766 cites W2013348842 @default.
- W1570208766 cites W2026673146 @default.
- W1570208766 cites W2057135034 @default.
- W1570208766 cites W2061894482 @default.
- W1570208766 cites W2069608198 @default.
- W1570208766 cites W2103602801 @default.
- W1570208766 cites W2103728369 @default.
- W1570208766 cites W2105558115 @default.
- W1570208766 cites W2130339421 @default.
- W1570208766 cites W2141001988 @default.
- W1570208766 cites W2146610973 @default.
- W1570208766 cites W2165059283 @default.
- W1570208766 cites W2166299500 @default.
- W1570208766 cites W2176723567 @default.
- W1570208766 cites W4235720348 @default.
- W1570208766 cites W4254883057 @default.
- W1570208766 cites W4321429576 @default.
- W1570208766 doi "https://doi.org/10.3171/2011.9.jns11177" @default.
- W1570208766 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22077447" @default.
- W1570208766 hasPublicationYear "2012" @default.
- W1570208766 type Work @default.
- W1570208766 sameAs 1570208766 @default.
- W1570208766 citedByCount "108" @default.
- W1570208766 countsByYear W15702087662012 @default.
- W1570208766 countsByYear W15702087662013 @default.
- W1570208766 countsByYear W15702087662014 @default.
- W1570208766 countsByYear W15702087662015 @default.
- W1570208766 countsByYear W15702087662016 @default.
- W1570208766 countsByYear W15702087662017 @default.
- W1570208766 countsByYear W15702087662018 @default.
- W1570208766 countsByYear W15702087662019 @default.
- W1570208766 countsByYear W15702087662020 @default.
- W1570208766 countsByYear W15702087662021 @default.
- W1570208766 countsByYear W15702087662022 @default.
- W1570208766 countsByYear W15702087662023 @default.
- W1570208766 crossrefType "journal-article" @default.
- W1570208766 hasAuthorship W1570208766A5011427447 @default.
- W1570208766 hasAuthorship W1570208766A5020032572 @default.
- W1570208766 hasAuthorship W1570208766A5022191739 @default.
- W1570208766 hasAuthorship W1570208766A5032556403 @default.
- W1570208766 hasAuthorship W1570208766A5042165288 @default.
- W1570208766 hasAuthorship W1570208766A5059099861 @default.
- W1570208766 hasAuthorship W1570208766A5061884581 @default.
- W1570208766 hasAuthorship W1570208766A5071859254 @default.
- W1570208766 hasAuthorship W1570208766A5077751691 @default.
- W1570208766 hasAuthorship W1570208766A5082744383 @default.
- W1570208766 hasConcept C126838900 @default.
- W1570208766 hasConcept C141071460 @default.
- W1570208766 hasConcept C146357865 @default.
- W1570208766 hasConcept C151730666 @default.
- W1570208766 hasConcept C2776035437 @default.
- W1570208766 hasConcept C2778749279 @default.
- W1570208766 hasConcept C2779603958 @default.
- W1570208766 hasConcept C2780387249 @default.
- W1570208766 hasConcept C2780643987 @default.
- W1570208766 hasConcept C2910939485 @default.
- W1570208766 hasConcept C2989005 @default.
- W1570208766 hasConcept C509974204 @default.
- W1570208766 hasConcept C71924100 @default.
- W1570208766 hasConcept C86803240 @default.
- W1570208766 hasConceptScore W1570208766C126838900 @default.
- W1570208766 hasConceptScore W1570208766C141071460 @default.
- W1570208766 hasConceptScore W1570208766C146357865 @default.
- W1570208766 hasConceptScore W1570208766C151730666 @default.
- W1570208766 hasConceptScore W1570208766C2776035437 @default.
- W1570208766 hasConceptScore W1570208766C2778749279 @default.
- W1570208766 hasConceptScore W1570208766C2779603958 @default.
- W1570208766 hasConceptScore W1570208766C2780387249 @default.
- W1570208766 hasConceptScore W1570208766C2780643987 @default.
- W1570208766 hasConceptScore W1570208766C2910939485 @default.
- W1570208766 hasConceptScore W1570208766C2989005 @default.
- W1570208766 hasConceptScore W1570208766C509974204 @default.
- W1570208766 hasConceptScore W1570208766C71924100 @default.
- W1570208766 hasConceptScore W1570208766C86803240 @default.